Market News
Stay updated with the latest market trends, earnings, and economic indicators.
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.
Sebi may widen 50% overlap rule to thematic passive mutual fund schemes
Curb on number of smart-beta schemes also likely; move aimed at curbing proliferation in segment

Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
SBI in $1 billion funding for Sun Pharma’s US deal
State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding underscores the growing ambition of Indian companies to expand globally.
Alkem Labs sees Rs 930 crore block deal as promoter family entities pare stake; Goldman, Morgan Stanley among key buyers
Alkem Laboratories shares experienced significant block deals totaling Rs 930 crore. Promoter family entities divested shares to a group of domestic mutual funds and foreign institutional investors. This transaction occurred after a strong performance by Alkem Laboratories shares over the past year. The deal highlights continued institutional interest in the pharmaceutical sector.

SBI Funds, Manipal Health set stage for a busy IPO market in second half of 2026
Manipal Health and SBI Funds are likely to lead a stronger second half for India’s IPO market despite geopolitical uncertainties. Their upcoming listings in June-July could pave the way for a broader pipeline of large and mid-sized public issues later this year.

Blue Jet Healthcare Q4 Results: Stock gains 10% despite weak earnings; Board approves fund raise
For the March quarter, Blue Jet Healthcare's Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) fell 49% to ₹71 crore from ₹140 crore a year ago, while EBITDA margin contracted sharply to 30.3% from 41%. Yet, the stock was up 10%.
Unique Picks: 6 stocks held by only one MF scheme in April, falling up to 40% in CY26
An analysis of mutual fund portfolios revealed 29 stocks held exclusively by single schemes, with most underperforming in CY26. However, Satin Creditcare Network, Rossell Techsys, and Amanta Healthcare bucked the trend, delivering strong returns. Brooks Laboratories and EFC (I) were among those experiencing significant declines.

Nippon India Mutual Fund raises stake in this healthcare stock. Do you own? - Mint
Nippon India Mutual Fund raises stake in this healthcare stock. Do you own?Mint
Where to invest now: SBI MF prefers large caps, pharma, PSU banks
Ruchit Mehta, Head of Research at SBI Mutual Fund, prefers CDMO and hospital plays within pharma, citing stronger growth prospects over generics. He sees large caps as attractive on valuations, while midcaps require selectivity amid earnings risks. PSU banks may outperform in the near term due to stronger loan growth, but asset quality risks could emerge over the next 2–3 quarters if global disruptions persist.

Stocks to Buy: Citi projects 20% upside for a stock that Mutual Funds lapped up in March
Citi expects Anthem Bio's revenue to grow at a 19% CAGR over financial year 2026-2028 and its Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) to grow at a 22% CAGR during the same timeframe.